IO102-IO103: Molecular Structure

Molecular Structure#

IO102-IO103 (Cylembio) is a therapeutic cancer vaccine composed of two distinct synthetic long peptides, each designed to target a different immunosuppressive pathway in the tumor microenvironment. Unlike most peptide therapeutics that act as receptor agonists or antagonists, IO102-IO103 peptides function as antigens -- they prime the adaptive immune system to mount cytotoxic T cell responses against specific tumor-associated targets.

IO102: IDO-Targeting Peptide#

IO102 is a synthetic long peptide derived from the indoleamine 2,3-dioxygenase (IDO) protein:

• Target protein: IDO (also known as IDO1), an intracellular enzyme that catalyzes the first and rate-limiting step of tryptophan degradation via the kynurenine pathway
• Function: IDO is overexpressed by tumor cells and myeloid-derived suppressor cells, creating an immunosuppressive microenvironment
• Peptide design: Engineered to contain epitopes that are processed by antigen-presenting cells and presented on both MHC class I (to activate CD8+ cytotoxic T cells) and MHC class II (to activate CD4+ helper T cells)
• Exact sequence: Proprietary to IO Biotech

IO103: PD-L1-Targeting Peptide#

IO103 is a synthetic peptide encoding amino acids 9-27 of human PD-L1 (CD274):

• Target protein: PD-L1 (programmed death ligand 1), a transmembrane protein that suppresses T cell function by engaging PD-1
• Sequence region: Amino acids 9-27 of the PD-L1 extracellular domain
• Function: Activates T cells that recognize and kill PD-L1-expressing cells, complementing the antibody-mediated PD-1/PD-L1 blockade provided by checkpoint inhibitors
• MHC presentation: Designed for broad HLA coverage to ensure immunogenicity across diverse patient populations

Vaccine Immunology Principles#

IO102-IO103 operates on several key principles of cancer vaccine immunology:

Long Peptide Advantage#

Long peptides (typically 20-35 amino acids) offer advantages over short peptides (8-10 amino acids) for cancer vaccination:

1. Professional APC processing: Long peptides are too large for direct loading onto MHC molecules and require uptake and processing by professional antigen-presenting cells (primarily dendritic cells)
2. Cross-presentation: Dendritic cells can cross-present long peptide epitopes on both MHC class I and class II molecules
3. Dual T cell activation: This engages both CD8+ cytotoxic T cells and CD4+ helper T cells
4. Depot effect: Longer peptides persist at the injection site, particularly when formulated with Montanide ISA-51 adjuvant

Montanide ISA-51 Adjuvant#

The peptides are formulated with Montanide ISA-51, a water-in-oil emulsion adjuvant:

• Creates a slow-release depot at the injection site
• Enhances uptake by antigen-presenting cells
• Promotes innate immune activation that supports adaptive immunity
• Establishes a sustained antigenic stimulus for robust T cell expansion

Molecular Properties#

Pharmacological Considerations#

Immune Response as the Endpoint#

Unlike traditional peptide therapeutics where plasma concentration drives effect, IO102-IO103 efficacy depends on the magnitude and quality of the vaccine-induced T cell response:

• T cell priming: Initial vaccination activates IDO-specific and PD-L1-specific T cells
• Clonal expansion: Repeated vaccination expands these T cell populations
• Memory formation: Long-lived memory T cells provide ongoing immune surveillance
• Effector function: Vaccine-activated T cells infiltrate tumors and kill IDO+ and PD-L1+ cells

Duration of Immune Effect#

The 5-year follow-up of the MM1636 trial demonstrated that vaccine-induced immune modulation can be remarkably durable:

• Median duration of response: >53 months
• Vaccine-specific immune signatures detectable at 5 years
• Suggests long-lived immune memory is established

Off-the-Shelf Design#

A key molecular design principle of IO102-IO103 is its off-the-shelf nature. The vaccine targets proteins that are:

• Universally expressed across most tumor types (IDO and PD-L1)
• Not patient-specific or mutation-dependent
• Present on both tumor cells and immunosuppressive immune cells

This contrasts with personalized neoantigen vaccines (e.g., mRNA-4157/V940) that require:

• Tumor biopsy and whole-exome sequencing
• HLA typing and neoantigen prediction
• Patient-specific vaccine manufacturing (weeks to months)

Related Reading#

• IO102-IO103 overview and research guide
• Peptides similar to IO102-IO103
• IO102-IO103 research evidence